ProCE Banner Activity

CE / CME

Advancing Care for HR+/HER2- Breast Cancer: Managing Patients With CDK4/6 Inhibitors

PCE On Demand Live Presentation

The addition of a CDK4/6 inhibitor to endocrine therapy (ET) has become standard of care in the treatment of patients with HR-positive/HER2-negative metastatic breast cancer. Abemaciclib is also approved in the adjuvant setting for patients with node-positive, high-risk hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. As the 3 FDA approved CDK4/6 inhibitors all vary in their dosing and administration, potential adverse events (AEs), and recommended monitoring, it is critical that healthcare professionals have an in-depth understanding of these medications. In this activity, an expert reviews the data supporting CDK4/6 inhibitors in both the metastatic and early-stage settings, management of potential AEs, differences in dosing and administration, and strategies to optimize patient adherence.

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: December 30, 2022

Expiration: December 29, 2023

No longer available for credit.

Share

Faculty

Jeremy M. Force

Jeremy M. Force, DO

Assistant Professor
Department of Medicine
Division of Medical Oncology
Breast Oncology Program
Duke University
Durham, North Carolina

Kathleen Madden

Kathleen Madden, MSN, ANP-BC, AOCNP

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

After completing this activity, participants should be better able to:

  • Develop guideline-directed, individualized treatment approaches for use of CDK4/6 inhibitors in HR-positive/HER2-negative early and advanced breast cancer

  • Implement recommended strategies for identifying and managing toxicities associated with CDK4/6 inhibitors

  • Integrate patient education and feedback to optimize patient experiences during treatment and survivorship

Disclosure

All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Jeremy Force, DO: consultant/speaker: Nanostring, Pfizer; researcher: Exact Sciences, G1 Therapeutics, Xilis.

Christie Hilton, DO: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo.

Kathleen Madden, MSN: consultant/advisor/speaker: Novartis.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose, except Christie Hilton, DO, as noted above.

Instructions for Credit

Learners wishing to earn CE/CME credit must: 

  1. View the content in its entirety
  2. Relate the content material to the learning objectives 
  3. Complete evaluation form 

The estimated time to complete this activity is 1.00 hour.

Release date: December 30, 2022
Expiration date: December 29, 2023

Format

This program has been made available online.

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Partners for Advancing Clinical Education, Practicing Clinicians Exchange, or any educational supporter

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

 

AAPA Credit Designation
Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until December 29, 2023. PAs should only claim credit commensurate with the extent of their participation.

 

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.